Cargando…

Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)

Angiogenic T (Tang) cells are mediators of vascular repair, and are characterized by surface expression of CXCR4. This receptor for stromal cell‐derived factor‐1α (SDF‐1α) is cleaved by dipeptidyl peptidase‐4 (DPP‐4). Tang cell levels were investigated in people with type 2 diabetes mellitus (T2DM)...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Stefanie A., Reijrink, Melanie, Abdulahad, Wayel H., Hoekstra, Elisa S., Slart, Riemer H. J. A., Heerspink, Hiddo J. L., Westra, Johanna, Mulder, Douwe J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317866/
https://www.ncbi.nlm.nih.gov/pubmed/32166899
http://dx.doi.org/10.1111/dom.14024
_version_ 1783550725241962496
author de Boer, Stefanie A.
Reijrink, Melanie
Abdulahad, Wayel H.
Hoekstra, Elisa S.
Slart, Riemer H. J. A.
Heerspink, Hiddo J. L.
Westra, Johanna
Mulder, Douwe J.
author_facet de Boer, Stefanie A.
Reijrink, Melanie
Abdulahad, Wayel H.
Hoekstra, Elisa S.
Slart, Riemer H. J. A.
Heerspink, Hiddo J. L.
Westra, Johanna
Mulder, Douwe J.
author_sort de Boer, Stefanie A.
collection PubMed
description Angiogenic T (Tang) cells are mediators of vascular repair, and are characterized by surface expression of CXCR4. This receptor for stromal cell‐derived factor‐1α (SDF‐1α) is cleaved by dipeptidyl peptidase‐4 (DPP‐4). Tang cell levels were investigated in people with type 2 diabetes mellitus (T2DM) compared with matched healthy controls and after treatment with the DPP‐4 inhibitor Linagliptin. People with T2DM were randomized to 5 mg/day Linagliptin (n = 20) or placebo (n = 21) for 26 weeks. Tang cell frequency was identified in peripheral blood mononuclear cells (CD3(+)CD31(+)CXCR4(+)) and levels of endothelial progenitor cells (EPCs) (CD34(+)CD133(+)KDR(+)) were also assessed in whole blood. Circulating Tang cell levels were significantly lower in people with T2DM compared with the healthy control group. SDF‐1α levels increased significantly in Linagliptin‐treated people with T2DM compared to placebo, and a trend was observed in change of Tang cell levels, while EPC count did not change. In conclusion, circulating Tang cell levels were considerably lower in people with T2DM, while a trend was observed in recruitment of Tang cells after 26 weeks of treatment with Linagliptin. These data suggest that DPP‐4 inhibitors may potentially exert beneficial effects on bone marrow‐driven vascular repair.
format Online
Article
Text
id pubmed-7317866
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-73178662020-06-29 Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study) de Boer, Stefanie A. Reijrink, Melanie Abdulahad, Wayel H. Hoekstra, Elisa S. Slart, Riemer H. J. A. Heerspink, Hiddo J. L. Westra, Johanna Mulder, Douwe J. Diabetes Obes Metab Brief Reports Angiogenic T (Tang) cells are mediators of vascular repair, and are characterized by surface expression of CXCR4. This receptor for stromal cell‐derived factor‐1α (SDF‐1α) is cleaved by dipeptidyl peptidase‐4 (DPP‐4). Tang cell levels were investigated in people with type 2 diabetes mellitus (T2DM) compared with matched healthy controls and after treatment with the DPP‐4 inhibitor Linagliptin. People with T2DM were randomized to 5 mg/day Linagliptin (n = 20) or placebo (n = 21) for 26 weeks. Tang cell frequency was identified in peripheral blood mononuclear cells (CD3(+)CD31(+)CXCR4(+)) and levels of endothelial progenitor cells (EPCs) (CD34(+)CD133(+)KDR(+)) were also assessed in whole blood. Circulating Tang cell levels were significantly lower in people with T2DM compared with the healthy control group. SDF‐1α levels increased significantly in Linagliptin‐treated people with T2DM compared to placebo, and a trend was observed in change of Tang cell levels, while EPC count did not change. In conclusion, circulating Tang cell levels were considerably lower in people with T2DM, while a trend was observed in recruitment of Tang cells after 26 weeks of treatment with Linagliptin. These data suggest that DPP‐4 inhibitors may potentially exert beneficial effects on bone marrow‐driven vascular repair. Blackwell Publishing Ltd 2020-03-27 2020-07 /pmc/articles/PMC7317866/ /pubmed/32166899 http://dx.doi.org/10.1111/dom.14024 Text en © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Reports
de Boer, Stefanie A.
Reijrink, Melanie
Abdulahad, Wayel H.
Hoekstra, Elisa S.
Slart, Riemer H. J. A.
Heerspink, Hiddo J. L.
Westra, Johanna
Mulder, Douwe J.
Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
title Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
title_full Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
title_fullStr Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
title_full_unstemmed Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
title_short Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
title_sort angiogenic t cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor linagliptin: a subanalysis from a randomized, placebo‐controlled trial (release study)
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317866/
https://www.ncbi.nlm.nih.gov/pubmed/32166899
http://dx.doi.org/10.1111/dom.14024
work_keys_str_mv AT deboerstefaniea angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy
AT reijrinkmelanie angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy
AT abdulahadwayelh angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy
AT hoekstraelisas angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy
AT slartriemerhja angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy
AT heerspinkhiddojl angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy
AT westrajohanna angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy
AT mulderdouwej angiogenictcellsaredecreasedinpeoplewithtype2diabetesmellitusandrecruitedbythedipeptidylpeptidase4inhibitorlinagliptinasubanalysisfromarandomizedplacebocontrolledtrialreleasestudy